Diabetes 60 (11), 27752786
November 26th, 2025: Ozempic and Mounjaro Litigation Expands Following New Evidence of Heightened GI Risks A newly released study has increased scrutiny of GLP-1 receptor agonists such as Ozempic, Mounjaro, and Trulicity, linking these medications to substantially higher rates of gastrointestinal complications than older diabetes treatments
*Membership requires a one-time enrollment fee of $300, followed by a $150 monthly fee and cost of medication Weight Loss Membership Benefits Comprehensive lab panel Full initial visit InBody scan for precise tracking Monthly wellness consultations 12 weeks of GLP-1 medication Monthly B12 injection 50% Off Muscle Contouring Treatments Note: Memberships cannot be combined with other promotions
How to Learn More and Order If you're curious to explore this peptide further or ready to try it yourself, visit the official Healthletic product page below
5 earnings call its Q3 2025 net profit fell 27% YoY to $3.1 billion, after which its stock fell more than 2%